logo
Plus   Neg
Share
Email

Selecta Biosciences Eliminates 36% Of Workforce

Selecta Biosciences, Inc. (SELB) said that it restructured to reduce the current workforce by 36% as of January 3, 2019. The reduction, coupled with a reprioritization of the company's pipeline programs, is projected to reduce the yearly cash burn by 19% going forward.

SELB closed Thursday regular trading at $2.29, down $0.61 or 21.03 percent.

Effective December 1, 2018, Carsten Brunn, Ph.D., assumed the role of President and CEO of Selecta, following his previous position as President of Pharmaceuticals for the Americas and member of the Global Pharmaceutical Executive Committee at Bayer. He has also held senior executive positions at Eli Lilly, Novartis, Basilea, and Bausch and Lomb in Europe, Asia and the United States.

President and CEO, Carsten Brunn, said, "We believe 2019 will be a transformative year for Selecta with key milestones anticipated for both our chronic refractory gout and gene therapy programs. We intend to focus on executing our strategic priorities, advancing our ImmTOR platform, and growing our strategic partnerships."

Following a December 2018 U.S. Food and Drug Administration (FDA) meeting, the company plans to initiate a head-to-head superiority trial of SEL-212, utilizing revised stopping rules, compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019.

In September 2018, Selecta announced a collaboration with the European consortium, CureCN, for an ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar Syndrome. Selecta expects CureCN to initiate preclinical toxicology studies in the first half of 2019 and for the combination product candidate to enter the clinic in the second half of the year.

Selecta plans to deprioritize its SEL-403 Phase 1 oncology program. The trial, which was placed on clinical hold by the FDA, was being conducted by the National Cancer Institute, part of the National Institutes of Health.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>